Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic pooling
PubMed 41714473 · doi:10.1007/s40257-026-01009-2
What was done
This narrative review synthesized the pathophysiology, diagnostic evaluation, differential diagnosis, and current management landscape for androgenetic alopecia in women. It summarized evaluated diagnostic tools (such as trichoscopy, pull testing, and trichometric measurements) and therapeutic options spanning the single FDA-approved drug, off-label medications (low-dose oral minoxidil, spironolactone, finasteride, dutasteride), surgical hair transplantation, and procedural adjuncts (low-level light therapy, platelet-rich plasma).
What was found
The abstract provides no primary experimental data, sample sizes, or quantitative outcome measures. It notes an epidemiological estimate that androgenetic alopecia affects nearly 50% of women during their lifetime. Topical minoxidil is highlighted as the only FDA-approved therapy, with all other discussed pharmacologic options used off-label. The authors emphasize a persistent lack of randomized controlled trials enrolling female patients.
Why it matters
Female pattern hair loss carries severe psychosocial consequences, yet clinical management relies heavily on off-label regimens due to a lack of dedicated randomized trials. This paper outlines current clinical practice and highlights the research gaps preventing broader approved therapies.
Limits
As a narrative review, this work does not follow systematic review methods, include risk-of-bias assessments, or perform meta-analytic pooling. No primary trial data, effect estimates, or statistical comparisons are reported in the abstract.
Cited by
- supports Androgenetic alopecia involves androgen-induced miniaturization of the hair follicle and a progressive shortening of the anagen growth phase.